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ABSTRACT
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous
mutations in the activin A type I receptor (ACVR1), that encodes the bonemorphogenetic protein (BMP) type I receptor ALK2. Thesemuta-
tions enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents. To date,
there is no cure for FOP. The further development of FOP patient-derived models may contribute to the discovery of novel biomarkers
and therapeutic approaches. Nevertheless, this has traditionally been a challenge, as biopsy sampling often triggers HO. We have char-
acterized peripheral blood-derived endothelial colony-forming cells (ECFCs) from three independent FOP donors as a newmodel for FOP.
FOP ECFCs are prone to undergo endothelial-to-mesenchymal transition and exhibit increased ALK2 downstream signaling and subse-
quent osteogenic differentiation upon stimulationwith activin A.Moreover, we have identified a new class of small moleculemacrocycles
with potential activity against ALK2 kinase. Finally, using FOP ECFCs, we have selected OD36 andOD52 as potent inhibitors with excellent
kinase selectivity profiles that potently antagonizemutant ALK2 signaling and osteogenic differentiation.We expect that these results will
contribute to the development of novel ALK2 clinical candidates for the treatment of FOP. © 2019 The Authors. JBMR Plus published by
Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Heterotopic ossification (HO) is a musculoskeletal disordercharacterized by bone formation at extraskeletal sites, such
as soft tissues and joints. Fibrodysplasia ossificans progressiva
(FOP; MIM #135100) is a devastating congenital disorder involv-
ing HO. FOP is an extremely rare disease (1 affected per
2,000,000 individuals) associated with mutations in the activin
A type I receptor (ACVR1) gene, encoding the BMP type I receptor
kinase ALK2.(1) Based on overexpression studies, early publica-
tions suggested that the mutant ALK2 receptor becomes hyper-
sensitive to classical BMP ligands, or even constitutively active
because of the impaired interaction with the type I receptor
inhibitor FKBP12,(2) which led to the development of BMP type
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I receptor kinase inhibitors to prevent ALK2 downstream signal-
ing.(3) Two recent publications have shown that the recurrent
ACVR1 c.617G > A (ALK2 R206H) mutation enables ALK2 to
transduce downstream signaling through the BMP-specific
Smad1/5/8 pathway in response to activins,(4,5) a subset of
ligands of the TGF-β family, which normally induce Smad2/3 sig-
naling via ALK4. Activins are released during inflammatory
events, which may help to explain the intermittent progression
of the disease, through episodes of inflammation triggered, for
example, by viral infections, physical trauma, and importantly
by biopsy sampling. Today, there remains no cure for FOP.
Broad-spectrum anti-inflammatories are commonly used to
ameliorate flare-ups, but demonstrate little benefit.
Together with recent advances in the development of animal
models of the disease,(4,6–9) the establishment of patient-derived
models of FOP may contribute to study specific aspects of the
disease, such as monitor disease progression or the phenotypic
variability among patients with a common mutation. Despite
the recent generation of induced pluripotent stem cell (iPSC)
lines from FOP somatic tissues in past years,(10–12) the establish-
ment and maintenance of such lines remains time- and
resource-consuming, and is restricted to groups with expertise
in iPSC technology. Therefore, new model systems making use
of different cell types are progressively arising.(13,14)
In this study, we have established cell cultures of circulating
endothelial colony-forming cells (ECFCs) from the peripheral
blood of FOP donors, collected during routine blood tests. FOP
ECFCs express the mutant ACVR1/ALK2 receptor and are respon-
sive to activin A, inducing Smad1/5/8 activation and signaling.
We have found that FOP ECFCs exhibit a higher BMP kinase
receptor-dependent osteogenic potential in vitro when com-
pared with control ECFCs. Furthermore, we explored a new class
of ALK2 kinase inhibitors from a small-moleculemacrocyclic plat-
form comprised of an ATP-mimetic scaffold and a functionalized
linker. These compounds share a low molecular weight, have
predictable structure–activity relationships, and drug-like prop-
erties. Through in vitro tests in FOP ECFCs, we have identified
two novel specific macrocyclic kinase inhibitors of activin-
inducedmutant ALK2 signaling, withminimum effects on closely
related BMP receptors. We have compared the ALK2 binding and
kinase profiling between these two newmolecules and the most
studied BMP type I kinase receptor inhibitor, LDN-193189, con-
firming their enhanced specificity for the mutant ALK2.
Altogether, we hereby introduce a new easy-to-establish
in vitro platform to investigate FOP patient-derived cells and its
application in the identification of novel ALK2 inhibitors for
FOP. These findings hold promise to help the development of
future therapeutic options for this currently untreatable disease.
Materials and Methods
Cell lines and reagents
Mouse C2C12 myoblast cells and mouse endothelial cells 2H11
were maintained in DMEM medium (Gibco, Carlsbad, CA, USA)
supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA),
and penicillin/ streptomycin (Invitrogen). For 2H11 cells, the
plates were pretreated with 0.1% gelatin (Sigma-Aldrich, St
Louis, MO, USA). Mouse osteoprogenitor cells KS483 were cul-
tured in α-MEM (Gibco) and 10% FBS (Invitrogen), and
penicillin–streptomycin (Invitrogen). Human umbilical vein
endothelial cells (HUVECs) were purchased from Lonza and cul-
tured in complete EGM-2 (Lonza, Walkerville, MD, USA) medium
supplemented with 10% FBS and 0,1% penicillin–streptomycin.
Mouse chondrogenic ATDC5 cells were cultured in phenol red
free DMEM-F12 (Gibco) containing 5% FBS. All of the cells were
grown at 37C in a humidified incubator with 5% CO2. BMP-6
was a kind gift from Dr S Vukicevic. TGF-β3 was provided by
Dr A Hinck. Activin A was purchased from R&D Systems
(Abingdon, UK). TNF-α was purchased from Pierce (Thermo
Fisher Scientific, Waltham, MA, USA).
Blood collection and ECFCs isolation
ECFCs represent an easy source of fully functional highly prolifer-
ative ECs from humans. The isolation protocol of human ECFCs
requires withdrawal of 30 to 60 mL of peripheral blood in
citrate-treated collection tubes, after obtaining written informal
consent in accordance with the institutional guidelines. Usually,
the first 2 mL of blood will be discarded to avoid contamination
with skin fibroblasts. The blood was prediluted 1:1 with pre-
warmed PBS and centrifuged at 740g for 30 min in the presence
of Ficoll Paque Plus (GE Healthcare Europe GmbH, Eindhoven,
The Netherlands), to separate a fraction containing mononuclear
cells (MNCs). These cells are collected and washed three times
with M199 (Lonza, Verviers, Belgium) supplemented with 0.1%
penicillin/streptomycin (Invitrogen, Leek, The Netherlands).
Finally, the cells are resuspended in complete EGM-2 (Lonza)
supplemented with 10% platelet lysate (PL-EGM) and 0,1%
penicillin–streptomycin and seeded at density of 1.3 × 106
cells/cm2 into 48-well plates precoated with 3 μg/cm2 human
collagen type I prepared according to the manufacturer’s
instructions (#C7624, Sigma Aldrich). After 24 hours, nonadher-
ent cells were carefully removed and fresh medium was added
to each well. From this moment, the medium is replaced every
day and supernatants discarded. ECFC colonies with regular cob-
blestonemorphology appear within 3 to 4 weeks. Isolated ECFCs
are then maintained in EGM-2 (Lonza) supplemented with 10%
FBS and 0.1% penicillin/streptomycin (Invitrogen).
Flow cytometric analysis of isolated ECFCs
Flow cytometric analysis (FACS) of isolated ECFCs was performed
as previously described.(15) Briefly, cells were dissociated using
1X TrypLE select (Invitrogen) and washed once with the FACs
buffer with 10% FBS, followed by an additional wash with FACs
buffer. A list of the antibodies used can be found as Online Sup-
plemental data. The samples were analyzed with the MACS-
Quant VYB (Miltenyi, Bergisch Gladbach, Germany) with the
following instrument settings: Blue/488 FITC, A488: 525/50; Yel-
low/561 PE: 586/15, APC: 661/20, APC-Cy7: 750 LP.
Genotype analysis
There were 100 ng of DNA subjected to PCR to amplify the exon
4 of ACVR1/ALK2 using hALK2ex4FW (CCAGTCCTTCTTCC
TTCTTCC) and hALK2ex4RV (AGCAGATTTTCCAAGTTCCATC), as
reported previously.(1) The PCR product was separated in a 1%
agarose gel and the 350-bp fragment was cut and purified using
Wizard (Promega, San Luis Obispo, CA, USA). Samples were sub-
mitted to Sanger sequencing using both hALK2ex4FW and
hALK2ex4RV oligonucleotides.
Quantitative real-time RT-PCR (qPCR)
Total RNA extraction was performed using NucleoSpin RNA II
(Machery Nagel, Düren, Germany). There were 500 ng of RNA
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retro-transcribed using RevertAid First Strand cDNA Synthesis
Kits (Fisher Scientific, Landsmeer, The Netherlands), and real-
time reverse transcription-PCR experiments were performed
using SYBR Green (Bio-Rad, Veenendaal, The Netherlands) and
a Bio-Rad CFX Connect device. A list of the oligonucleotides used
can be found as online supplemental data.
Mineralization assays
For mineralization assays, 5 × 104 ECs were seeded into 48-well
plates and incubated in osteogenic medium containing
10−8M/L dexamethasone, 0.2mM/L ascorbic acid, and 10mM/L
β-glycerolphosphate in the presence of BMP/ TGF-β ligands for
28 days. The medium was refreshed every 4 days. Afterwards,
cells were washed twice with PBS and fixed with 3.7% formalde-
hyde for 5 min. Next, cells were washed twice with distilled
water; measurement of calcium deposition was performed by
Alizarin Red solution (ARS) staining, as previously described.(16)
Precipitates, originated from three independent ARS assays,
were dissolved using 10% cetylpyridinium chloride, and absor-
bance was measured at 570 nm. Representative pictures were
obtained using a Leica DMIL LEDmicroscope (Leica, Wetzlar, Ger-
many) with 10× magnification.
Chondrogenic differentiation assays and adenovirus
transduction
Forty-eight hours before starting the micromass assay, the ATDC5
cells were transduced with the same titer of adenoviral particles
in the presence of Polybrene (4 mg/mL), encoding for either the
ALK2wt-HA or ALK2R206H-HA (previously described(2)). Briefly,
ATDC5 cells were trypsinized and washed once with PBS. There
were 3 × 105 cells counted per micromass, and resuspended in
10 μL of culture medium. Very carefully, 100-μL drops were depos-
ited in the center of the well in a 24-wells plate and placed in the
incubator for 2 hours. Next 500 μL of DMEM-F12 5% FBS contain-
ing 1X ITS (Gibco) were carefully added to the wells. After 24 hours,
themediumwas replaced by DMEM-F12 5% FBS containing 1X ITS,
supplemented with BMP-6 or activin A (100 ng/mL), and DMSO,
LDN-193189, OD36, or OD52 (0.5μM). The cells were incubated
for 21 days before further analysis, refreshing the medium every
5 days. To stain the pellets, cells were fixed for 15 min in 500 μL
of fixative solution (30% EtOH, 0.4% PFA, and 4% acetic acid). Next,
the fixative solution was removed and the pellets were incubated
overnight at 37C in Alcian Blue staining solution (0.05% Alcian
Blue staining solution in 75% EtOH:0.1M HCl [4:1]). Finally, the cells
were washed and pictures acquired using a Leica DMIL LED micro-
scope with 10×magnification. Subsequently, the staining was sol-
ubilized in 250 μL of 6 guanidine hydrochloride (Sigma-Aldrich)
and quantification was performed by absorbance at 595 nm.
Statistical analysis
Student’s t test was used for statistical analysis and p < 0.05 was
considered to be statistically significant. All experiments were
performed at least in triplicate, unless indicated.
Results
Establishment and characterization of FOP ECFCs
We used a previously reported minimally invasive protocol(17) to
isolate endothelial-colony-forming cells (ECFCs) from the periph-
eral blood of FOP patients diagnosed with the FOP classical
variant (see Supplementary Table S1 for donor characteristics).
Confluent ECFCs under the microscope exhibited an
endothelial-like appearance (Fig. 1A), with apparently no mor-
phological differences between the control and FOP colonies
as seen upon cytoskeleton F-actin staining (Fig. 1B). Next, we
confirmed the presence of the classical heterozygous ACVR1/
ALK2 (c.617G > A; R206H) mutation in our three FOP donors
(Fig. 1C). To substantiate the endothelial characteristics of the
cultures, we determined by flow cytometry analysis (FACS) the
surface expression of the endothelial-specific proteins vascular
endothelial (VE) cadherin; platelet endothelial cell adhesion mol-
ecule (PECAM-) 1; vascular endothelial growth factor receptor-
(VEGFR-) 2, CD105, and Tie-2; the hematopoietic marker CD34;
and the immune cell markers CD14 and CD45 (Fig. 1D). Both con-
trol and FOP ECFCs were negative for the immune markers CD14
and CD45, and expressed similar levels of endothelial proteins as
human umbilical vein endothelial cells (HUVECs), used as a refer-
ence. Of note, control and FOP ECFCs express PDGFRα
(Supplementary Fig. S1A), which has been shown to be
expressed by fibroadipogenic progenitor cells in mouse models
of FOP.(8) The mean PECAM-1 expression was significantly lower
in FOP ECFCs, compared with controls (Fig. 1E), which is sugges-
tive of a process named endothelial-to-mesenchymal transition
(EndMT), by which ECs lose their phenotypic characteristics and
progressively become fibroblast-like cells, susceptible to further
differentiation into chondrocytes or osteoblasts.(13) Endothelial
cells overexpressing the FOP mutant ALK2 receptor are prone
to undergo EndMT in response to TGF-β and BMP ligands.(18) In
addition, EndMT has been unveiled as a key phenomenon for
proper cardiovascular development and evidence for its contri-
bution to the onset and progression of postnatal cardiovascular
disease is accumulating.(19) To investigate whether FOP ECFCs
may be sensitized to undergo EndMT and become fibroblast-like
cells, we performed immunofluorescent labeling (Fig. 2A,B) and
qPCR analysis (Supplementary Fig. S1B) for the endothelial
markers PECAM1 and CDH5 (encoding for Ve-cadherin) and the
mesenchymal markers fibronectin (FN1), SM22α (TAGLN), and
N-cadherin (CDH2). Furthermore, because EndMT is induced in
response to inflammation, we investigated whether control
and FOP ECFCs display a mesenchymal phenotype in response
to the proinflammatory cytokine tumor necrosis factor (TNF)-α.
FOP ECFCs did express notoriously higher levels of the mesen-
chymal markers fibronectin (FN1) and SM22α (TAGLN) than
control ECFCs, whereas there were no evident differences in
Ve-cadherin expression. Moreover, FN1 and CDH2 were signifi-
cantly upregulated, whereas PECAM1was downregulated in con-
trol and disease cell lines in response to TNF-α. Finally, whereas
we failed to amplify the tendon-specific HO progenitor gene
marker SCX by qPCR (data not shown), we found that MX1
expression was induced in control and FOP ECFCs in response
to inflammation, suggesting that FOP ECFCs may resemble the
phenotype of muscle resident injury-induced HO progenitor
cells in humans(20) (Supplementary Fig. S1C).
FOP ECFCs exhibit an enhanced osteogenic response to
activin A
The recent discovery, concerning the neofunction of ALK2
R206H enabling the receptor to respond to activin, has
highlighted a novel mechanism by which mutant ALK2 induces
HO in FOP in an ALK2 kinase activity-dependent manner.(4) To
validate ECFCs as a surrogate model for FOP, we first confirmed
the expression of ACVR1 by qPCR (Supplementary Fig. S2).
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Analysis of the expression of the TGF-β and BMP receptors and
coreceptors revealed a significant increase in the mRNA levels
of ACVR1L, ACVR1B, BMPR2, and TDGF1 in FOP-derived ECFCs.
Next, we analyzed the effect of recombinant activin A adminis-
tration on canonical Smad 1/5 signaling. As shown in Fig. 3A,
exclusively FOP ECFCs responded to activin A by inducing the
phosphorylation of Smad 1/5 (p-Smad1/5), and the expression
of ID-1, ID-3, and Smad6, which are downstream of
ALK2-Smad1/5 signaling (Fig. 3B). Of note, control and FOP
ECFCs displayed a similar Smad2/3 phosphorylation (p-Smad2/3)
in response to activin A, suggesting that the classical
ALK4-activin A pathway remains unaffected in FOP ECFCs. Fur-
thermore, p-Smad2/3 was similarly induced by TGF-β in control
and FOP cells. Accordingly, we did not find significant
Fig. 1. Establishment of control and fibrodysplasia ossificans progressiva (FOP) endothelial colony-forming cell (ECFC) cultures. (A) Bright field represen-
tative images of three independent confluent control (CON#1, CON#2 and CON#3) and FOP (FOP#1, FOP#2 and FOP#3) ECFCs. PHA: phalloidin. (B) Cell
morphology in control and FOP ECFCs is shown upon phalloidin staining. Nuclei are visualized in blue (4,6-diamidino-2-phenylindole). (C) Sanger sequenc-
ing of ACVR1/ALK2 exon 4 shows the classical heterozygous (c.617G > A; R206H) mutation in FOP ECFCs. (D) Flow cytometry analysis of EC (Ve-Cadherin,
PECAM-1, VEGFR2, CD105, and Tie2), immune cell (CD14 and CD45), and hematopoietic (CD34) markers in control and FOP ECFCs. (E) Mean fluorescent
intensity of three independent control and FOP ECFCs. ***p < 0.001.
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Fig. 2. Fibrodysplasia ossificansprogressiva (FOP) endothelial colony-formingcells (ECFCs) are prone toundergoendothelial-to-mesenchymal transition (EndMT)
in response to TNF-α. Control (CON#1, CON#2andCON#3) andFOP (FOP#1, FOP#2, andFOP#3) ECFCswere stimulatedwith TNF-α (10 ng/mL) for 24 hoursprior to
immunofluorescent labeling for either Ve-cadherin (VECAD, green), fibronectin (FIBRO, red), and PECAM1 (PECAM, magenta) (A) or Transgelin (SM22α, green), N-
cadherin (NCAD, red), andPECAM1 (PECAM,magenta) (B). Nuclei are visualized inblue (4,6-diamidino-2-phenylindole). Representative confocal images are shown.
JBMR® Plus DEVELOPMENT OF MACROCYCLE KINASE INHIBITORS FOR ALK2 5 of 13 n
Fig. 3. Fibrodysplasia ossificans progressiva (FOP) endothelial colony-forming cells (ECFCs) activate Smad1/5 signaling in response to activin A, and
exhibit an enhanced osteogenic potential. (A) Phospho-Smad1/5, phospho-Smad2/3 and total Smads Western blot analysis in control and FOP ECFCs
stimulated after serum starvation with either activin A (50 ng/mL), BMP-6 (50 ng/mL), or TGF-β (5 ng/mL) for 45 min. (B) Expression of the BMP-target
genes ID1, ID3, and Smad6 and the TGF-β target genes CTGF, Col1a1, and Pai-1 in control and FOP ECFCs stimulated with either activin A (50 ng/mL)
or BMP-6 (50 ng/mL) for 3 hours. (C) Alizarin Red solution staining in control and FOP ECFCs incubated with either activin A (50 ng/mL) or BMP-6
(50 ng/mL) under osteogenic conditions. One representative image is shown per clone. (D) Quantification of (C) by absorbance upon solubilization of
calcium deposits in cetylpyridinium. GM: growth medium; OM: osteogenic medium. (E) Expression of the osteogenic genes alkaline phosphatase
(ALP), osterix (Osx), and Runx2 in control and FOP ECFCs incubated under osteogenic conditions with or activin A or BMP-6 (50 ng/mL). *p < 0.05,
**p < 0.01, ***p < 0.001.
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differences in the activation of the Smad3 target genes connec-
tive tissue growth factor (CTGF), collagen-1-alpha-1 (Col1a1), or
serpine-1 (Pai-1) (Fig. 3B).
ECs overexpressing the FOP mutant ACVR1/ALK2 receptor
have been reported to undergo EndMT in response to BMP-4
and TGF-β, and to differentiate into osteoblasts.(18) Based on
those results, we established an in vitro model to differentiate
ECFCs into osteogenic cells. We incubated control and FOP
ECFCs in osteogenic medium for 4 weeks and visualized the
deposition of calcified matrix by ARS staining (Fig. 3C). Stained
deposits were subsequently dissolved and quantified by absor-
bance (Fig. 3D). FOP ECFCs exhibited an enhanced staining
under basal osteogenic conditions, whereas cells incubated in
normal growth medium were not stained by ARS. Interestingly,
BMP-6 induced the formation of calcium deposits at a similar
level in control and FOP ECFCs, whereas activin A induced signif-
icantly more ARS staining in FOP ECFCs. These results were sup-
ported by the analysis of the expression of the osteoblast-
specific genes alkaline phosphatase (ALP), osterix (Osx), and
Runx2 by qPCR (Fig. 3E). As predicted from previous work,(4) both
activin A-induced Smad1/5 phosphorylation and subsequent
osteogenic differentiation were inhibited upon treatment with
the ALK2 kinase inhibitor LDN-193189 (Fig. 6D–F), demonstrating
a requirement for the kinase activity of ALK2 for these responses.
Identification of two novel macrocyclic inhibitors OD36
and OD52 with potent binding to the ALK2 kinase ATP
pocket
The dependence of the pathological signaling in FOP on ALK2
kinase activity has stimulated the development of the first small
molecule ALK2 inhibitors.(3,21,22) We decided to use an alterna-
tive approach to develop a novel class of molecules antagoniz-
ing ALK2 kinase activity. The nanocyclix platform is a
chemistry-based platform of small-molecular-weight macro-
cycles, designed as ATP-competitive type 1 inhibitors. Their
unique tridimensional shape is thought to be at the origin of
their affinity and selectivity. Among other inhibitors with affinity
for receptor interacting serine/threonine kinase 2 (RIPK2),(23) we
identified a chemical series with high affinities against ALK2,
while displaying interesting selectivity (including OD36). Further
characterization highlighted a good selectivity against the other
members of the BMP receptor family, as seen in Supplementary
Table S2. A first round of optimization, consisting of the modifica-
tion of the linker focused on the improvement of selectivity, led to
the identification of the lead compound OD52, displaying similar
affinities against ALK2, while improving overall kinase selectivity
and significantly improving solubility (Supplementary Tables S2
and S3). As Fig. 4A–C shows, whereas LDN-193189 showed a poor
selectivity, inhibiting over 50% of the activity in 8.3% of all kinase
activities tested, OD36 and OD52, in particular, displayed an
improved selectivity (only 4.3% and 0.9% of tested kinases were
inhibited). This was further validated by the determination of the
KD values of OD36 and OD52 against kinase receptors of the
TGF-β and BMP family (Fig. 4D). Importantly, OD36 andOD52 both
showed ALK2-directed activity with KD values of 37nM and 9.6nM,
respectively (Fig. 4D). In addition, we determined the in vitro IC50
values against the WT and mutant R206H receptor kinase
domains, which showed an enhanced activity for the mutant
receptor. Finally, we solved the crystal structure of OD36 in com-
plex with ALK2 refined at 2.56 Å resolution (PDB ref. 5OY6)
(Fig. 4E, Supplementary Table S4). Comparison of the binding
modes of OD36 and LDN-193189 in the ALK2 ATP pocket
(Fig. 4F) revealed a common positioning of the pyrazolo[1,5-a]
pyrimidine groups, allowing a single hydrogen bond to the ALK2
hinge residue His286, while the phenylchloride moiety of OD36
occupied the back pocket similar to the 4-quinoline of LDN-
193189. Themacrocyclic linker inOD36 also afforded an additional
water-mediated hydrogen bond to Asp293. In silico modeling of
OD52 based on the OD36 cocrystal revealed a conserved binding
mode, but predicted two additional hydrogen bonds from the var-
iable linker to Tyr219 and Lys340, respectively (Fig. 4G).
OD36 and OD52 represent a new class of BMP receptor
inhibitors with enhanced specificity for ALK2 kinase
activity
We next tested OD36 and OD52 in traditional cell models to
assess BMP activity, using murine preosteoblast KS483 cells
transfected with the BMP responsive element- (BRE-) driven tran-
scriptional luciferase reporter construct BRE-LUC.(24) Stimulation
of the reporter activity using BMP-6, which signals through
ALK2, ALK3, and ALK6, was inhibited in a dose-dependent man-
ner in the submicromolar range by the macrocyclic inhibitors
OD36 and OD52, although with less potency than the reference
compound LDN-193189 (Fig. 5A). Using the TGF-β/Smad3
reporter construct CAGA-LUC,(25) we observed that OD36 and
OD52 had significantly less inhibitory effect on TGF-β-induced
gene transcription than LDN-193189 (Fig. 5B), consistent with
the recombinant kinase selectivity profiling. Congruently, OD36
and OD52 efficiently inhibited BMP-6- induced p-Smad1/5 in
KS483 cells (Fig. 5C). After confirming by ligand-binding affinity
assays with radiolabeled BMP-9 that BMP-9 mainly signals
through ALK2 in 2H11 ECs (Supplementary Fig. S3), we evaluated
the activity of OD36 and OD52 to specifically inhibit
ALK2-induced signaling by stimulating these cells with either
BMP-6 or BMP-9. As Fig. 5D shows, LDN-193189 efficiently
blocked p-Smad1/5 in response to both BMP-6 and BMP-9,
whereas OD36 and OD52 only inhibited BMP-9-induced p-
Smad1/5. Next, we cotransfected C2C12 murine myofibroblast
cells with constitutive active (ca) constructs of the BMP type I
receptors ALK1, ALK2, ALK3, and ALK6 and the BRE-LUC con-
struct.(26) Interestingly, whereas LDN-193189 significantly inhib-
ited caALK1/2/6 at 0.5μM, OD36 and OD52 exclusively inhibited
ALK2 (Fig. 5E). Finally, to compare the IC50 of OD36, OD52, and
LDN in living cells, we performed a reporter assay in C2C12 cells
cotransfected with the BMP reporter construct BRELUC and
either the WT or the mutant ALK2 R206H. Noteworthy, when
testing different concentrations (0, 0.05, 0.1, 0.25, 0.5, 1, 2.5,
5μM) of the indicated compounds, the IC50 of LDN was compa-
rable to that of OD36 and OD52 in cells stimulated with activin
A in the presence of the mutant receptor (Fig. 5H), which is not
the case in cells stimulated with BMP-6, irrespective of overex-
pressing the WT or the mutant ALK2 (Fig. 5F,G). Altogether, this
demonstrates the specificity of OD36 and OD52 for ALK2.
OD36 and OD52 inhibit activin A-induced ALK2 R206H
osteogenic and chondrogenic differentiation
To test the potential of OD36 and OD52 to block endochondral
ossification in FOP, we used ATDC5 chondrogenic progenitors
as a previously validated model system.(27) Using adenoviruses,
we transduced ATDC5 with vectors encoding for the WT or the
mutant R206H ALK2 receptor. As shown in Supplementary
Fig. S4, ATDC5-ALK2 R206H exhibited a significant increase in
Alcian Blue staining with respect to ATDC5-ALK2 WT in response
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to activin A stimulation, which was further supported by the
expression analysis of the chondrocyte genes Sox9, Mmp13,
and ColX. In this model, LDN (0.5μM) indistinctly inhibited BMP-
6 and activin A-induced chondrogenic differentiation. OD36
and OD52 (0.5μM), however, exhibited a very potent inhibitory
effect on activin A-induced chondrogenic differentiation, while
showing a minor response to BMP-6 (Fig. 6A–C). Finally, we
determined the effect of these two compounds in FOP ECFCs
subjected to osteogenic differentiation, therefore resembling a
FOP human genetic background. As shown in Fig. 6D and 6E,
preincubation of FOP ECFCs with OD36 and OD52 completely
prevented the activation of Smad1/5 and gene targets ID-1 and
ID-3 in response to activin A, whereas they were less effective
on BMP-6 induced downstream signaling. Furthermore, OD36
Fig. 4. ALK2 binding and kinase profile of OD36 and OD52. The activity of a panel of 366–468 kinases was tested in the presence of 100nM of OD36 (A) or
OD52 (B) and compared with LDN-193189 (C), adapted and used with permission from Science (sciencemag.org) and Cell Signalling Technology (Danvers,
MA, USA). Circle size shows potency. (D) Summary of the affinity (Kd) of OD36, OD52, and LDN-193189 for the BMP and TGF-β type I and type II kinase
receptors, and the IC50 of the three ALK2 antagonists for theWT and R206H ALK2 receptor. (E) Cocrystal structure of ALK2 andOD36 (2.56 Å) and (F) super-
position with LDN-193189. (G) Model of OD52-ALK2 interaction based on shape complementary as predicted by modulus of elasticity (MOE).
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Fig. 5. The macrocyclic compounds OD36 andOD52 efficiently inhibit activin A-induced ALK2 R206H downstream signaling. (A) BMP BRE-LUC reporter assay
performed in KS483 preincubated with LDN-193189, OD36, or OD52 at the indicated concentrations, followed by stimulation with BMP-6 (50 ng/mL) for
16 hours. (B) TGF-βCAGA-LUC reporter assayperformed inKS483 cells preincubatedwithLDN-193189,OD36, orOD52at the indicated concentrations, followed
by stimulationwithTGF-β (5 ng/mL) for 16 hours. (C) Analysis of BMP-6-inducedSmad1/5phosphorylationandtotal Smad1expressionbyWesternblot inKS483
cells, in the presence of LDN-193189, OD36, or OD52. (D) Western blot of 2H11 endothelial cells stimulated with either BMP-6 (50 ng/mL) or BMP-9 (1 ng/mL),
upon preincubationwith LDN-193189, OD36, or OD52 at 0.5μM. (E) Cotransfections of BRE-LUC and constitutive active (ca) formsof theALK1/2/3/6 receptors in
C2C12 cells. Compounds were added for 16 hours at 0.5μMbefore luciferase activity was measured. Dose-dependent response of LDN-193189 (LDN), OD36, or
OD52 in C2C12 cells cotransfected with the BRE-LUC reporter plasmid and the WT (F) or R206H ALK2 receptor (G, H). Upon 30-min preincubation with the indi-
cated compounds, the cells were stimulated with BMP-6 (F, G) or activin a (H) (50 ng/mL) for 16 hours. IC50 is indicated. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 6. The macrocyclic compounds OD36 and OD52 efficiently inhibit activin A-induced chondrogenic and osteogenic differentiation in in vitro models of
Fibrodysplasia ossificans progressiva (FOP). (A) Chondrogenic differentiation micromass assay in ATDC5 cells overexpressing ALK2 R206H. Cells were incu-
bated for 21 days in chondrogenic medium containing BMP-6 or activin A (50 ng/mL) and LDN-193189, OD36, or OD52 at 0.5μM, prior to Alcian Blue staining.
(B) Quantification of Fig. 6A by absorbance, after solubilization with guanidine hydrochloride. (C) Chondrogenic gene expression analysis of collagen 2 (Col2),
Sox9, Matrixmetalloproteinase 13 (Mmp13), and collagen X (Col X) in ATDC5 cells corresponding to (A). (D) Western blot of a representative clone of FOP endo-
thelial colony-forming cells (ECFCs) incubatedwith LDN-193189, OD36, or OD52 (0.5μM)prior to stimulationwith BMP-6 (50 ng/mL) or activinA (50 ng/mL). (E)
Expression of the BMP target genes ID1 and ID3 by qPCR in FOP ECFCs stimulated with BMP-6 (50 ng/mL) or activin A (50 ng/mL) in the presence of the indi-
cated compounds at 0.5μM. (F) Alizarin Red solution staining on a representative clone of FOP ECFCs incubated under osteogenic conditions with BMP-6
(50 ng/mL) or activin A (50 ng/mL) and the indicated compounds. (G) Quantification of Fig. 6F by absorbance, after solubilization with cetylpyridinium. (H)
Osteogenic genes Collagen 1 alpha 1 (Col1a1), Runx2, and osterix (Osx) expression in a representative clone of FOP ECFCs incubated under osteogenic con-
ditions with BMP-6 (50 ng/mL) or activin A (50 ng/mL) and LDN-193189, OD36, or OD52 (0.5 μM). *p < 0.05, **p < 0.01, ***p < 0.001.
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and OD52 efficiently blocked activin A-induced osteogenic dif-
ferentiation of FOP ECFCs, but they showed a modest effect
upon stimulation with BMP-6 (Fig. 6F–H). This indicates that spe-
cific targeting of activin A-ALK2 FOP-induced signaling might be
sufficient to prevent osteogenic differentiation in FOP. In sum-
mary, we have introduced ECFCs from FOP donors as an
in vitro model of the disease, recapitulating the aberrant
response of FOP cells to activin, and unveiled macrocyclization
technology as a novel approach to generated ALK2 kinase inhib-
itors with improved specificity. We hope that our results will pro-
vide novel tools to encourage the development of validated and
safe therapeutic approaches for FOP.
Discussion
In this study, we introduced ECFCs as a novel in vitro model for
FOP and used it to identify novel specific inhibitors of activin A-
induced osteogenic differentiation. FOP ECFCs recapitulate the
pathogenicmechanisms underlying FOP, in particular, the induc-
tion of Smad1/5-mediated signaling by activin A, consistent with
recent publications.(4,5) Noteworthy, such ALK2 neofunction in
FOP ECFCs is sensitive to inhibitors of ALK2. We have developed
a new class of ALK2 kinase domain small-molecule antagonists,
consisting of macrocyclic compounds exhibiting an improved
selectivity for ALK2 against closely related TGF-β and BMP kinase
receptors. OD36 and OD52 bind to ALK2 through interaction
with the kinase hinge residue His286, but explore a larger area
within the ATP pocket than LDN-193189 because of their macro-
cycle linkers, which offer an improved shape complementarity
contributing to their high selectivity. Finally, using FOP-derived
ECFCs, as well as traditional in vitro model systems for BMP and
TGF-β, we have demonstrated that OD36 and OD52 specifically
inhibit ALK2 downstream signaling with enhanced selectivity
over more promiscuous BMP signaling pathways inhibitors,
therefore blocking activin A-ALK2 R206H-induced osteogenic
and chondrogenic differentiation.
After the discovery of the ACVR1 mutation associated with
FOP by sequencing different patient-derived biopsies (ie, lym-
phoblastic lines, buccal swabs, or blood samples),(1) efforts have
been focused to understand the aberrant mechanisms triggered
in patients, resulting in misregulated endochondral ossification.
The establishment of patient-derived models of FOP has been
traditionally impaired by the induction of HO upon tissue biopsy
sampling. Therefore, studies were often based on overexpres-
sion strategies that may result in experimental artifacts. Other
approaches have been pursued, including the collection of stem
cells from human exfoliated deciduous teeth (SHED),(28) or fibro-
blasts isolated from either the skin(14) or periodontal liga-
ments.(13) In parallel, different groups have engineered a
number of FOP animal models. To overcome the embryonic
lethality caused by the embryonic expression of ALK2 R206H,
the recently developed models express ACVR1 c.617G > A post-
natally, or in a tissue-specific manner. Such mouse models have
allowed the preclinical evaluation of different potential treat-
ments for FOP. In addition, in FOPmice different cell populations
have been described to mediate HO in a cell autonomous man-
ner, generally termed fibroadipogenic cells (FAPs).(8,20) None of
the human-derivedmodels aforementioned exhibit a phenotype
similar to that of FAPs.(8,18,20) Although iPSCs have facilitated
the establishment of patient-derived cell models, they remain
technically challenging, and time- and resource-consuming. Fur-
thermore, in the particular case of endothelial cells, whether
iPSC-derived endothelial cells exactly recapitulate the existent
endothelial cells in FOP patients is not known. For example,
FOP iPSC-derived endothelial cells do not proliferate normally,
and interestingly, do not induce ALK2 downstream signaling in
response to activin A,(11) suggesting that iPSC-endothelial cell
differentiation protocols may need to be optimized to obtain
mature FOP endothelial cells. In comparison with existing
methods, ECFCs are easily accessible and not invasive when
combined with routine blood withdraws. ECFCs are isolated fol-
lowing a protocol already used for the isolation of immune cells
from peripheral blood, which is minimallymodified to favor ECFC
colony proliferation and can be cultured for multiple passages.
ECFCs have been previously used as surrogates to study vascular
diseases (reviewed in(29)). Interestingly, a number of vascular
comorbidities have been reported in the few existing manu-
scripts containing patient-derived tissues, including ventricular
dysfunction with cardiac fibrosis(30) and pulmonary hypertension
caused by a decreased pulmonary vascular bed.(31) Both endo-
thelial dysfunction and, in particular, EndMT have been demon-
strated to contribute such adult pathologies.(32,33) Therefore,
we anticipate that ECFCs may be interesting to investigate these
secondary conditions in FOP. In addition, more frequent and
larger blood vessels were recently found in lesions from FOP
donors compared with nongenetic forms of HO.(34) Electron
microscopy analysis has revealed that vessels in FOP lesions are
usually leaky and hemorrhagic,(35) with some endothelial cells
coexpressing typical osteoblast and fibroblast markers.(18,36)
Considering the tight link between angiogenesis and osteogen-
esis, ECFCs may be useful to study antiangiogenic therapies in
FOP patients, which may provide therapeutic alternatives to pre-
vent HO in FOP.
The recent discovery that activin A induces p-Smad1 signaling
via mutant ALK2, has expanded the potential therapeutic strate-
gies to prevent HO signaling in FOP (reviewed in(37)), including
impairment of the activin A-ALK2 complex formation by means
of ligand traps of neutralizing antibodies, genetic downregula-
tion of ACVR1, and mutant ALK2 kinase-activity inhibition. Inter-
estingly, ALK2 was initially identified as an activin receptor,(38)
where it limits the activity of ALK2 BMP ligands through direct
competition for the kinase receptor.(39,40) Therefore, it should
be taken into account, however, that activin A antagonists may
interfere with the normal physiological functions of the ligand
through p-Smad2/3,(4) or compromising its BMP counterbalan-
cing effect, potentially leading to undesirable side effects.(41)
On the other hand, because of the high structural similarity
among the TGF-β and BMP receptors, and in particular BMP
receptors ALK1, ALK2, and ALK3, to date it has been difficult to
obtain molecules or scaffolds with enough ALK2 selectivity to
enter in clinical studies. In this regard, macrocyclization has
resulted in OD36 and OD52, with enhanced specificity for
ALK2. In contrast to the reference compound LDN-193189, the
macrocycles OD36 and OD52 inhibit activin A-induced p-Smad1
activity, while having less effect on BMP-6-induced downstream
signaling. This likely reflects the weaker inhibitory activity of
OD36 and OD52 towards ALK3 and ALK6, which may contribute
to BMP6 signaling, but not to the activin A-induced p-Smad1/5
pathway.
Nowadays there are at least seven therapies under consider-
ation for the treatment of FOP. Two of them, a human specific
antiactivin antibody (REGN2477, Regeneron, NCT03188666;
Regeneron Pharmaceuticals, Tarrytown, NY, USA) and a RARγ
agonist (Palovarotene, NCT02279095; Clementia, Montreal,
Canada) are currently in clinical trials. In addition, the mTOR
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inhibitor rapamycin (Sirolimus(42); Rapamune, Pfizer, New York,
NY, USA), the repurposed Src inhibitor anticancer drug saracati-
nib (AstraZeneca Pharmaceuticals, Cambridge, UK) that also
inhibits ALK2 signaling,(9) an anti-ALK2 blocking antibody by
Daiichi Sankyo (Tokyo, Japan) and Saitama University (Saitama,
Japan), and three ALK2 kinase inhibitors (Blueprint Medicines,
Cambridge, MA, USA; La Jolla Pharmaceutical Co, San Diego,
CA, USA; BioCryst Pharmaceuticals, Durham, NC, USA) have been
publicly reported. Apart from waiting for the outcome of clinical
trials where periodic systemic administration is considered, it
would be of interest to explore whether these drugs may be use-
ful applied locally, eg, surgery to remove heterotopic bone, or for
example, in combinations at a lower dose. This might be partic-
ularly relevant for drugs inhibiting HO via interfering with differ-
ent pathways.
In summary, we have introduced and characterized a novel
surrogate in vitro model for FOP that we expect to be helpful
in the development of new therapeutic approaches for FOP.
Overall, our data suggest that ECFCs can be a useful and cost-
effective model system to investigate the cellular and molecular
mechanisms underlying FOP with the potential to aid the future
identification of predictive flare-up biomarkers in FOP that are
critical for any therapeutic approach investigated. Additionally,
the discovery of macrocycles OD36 and OD52 represents a new
class of ALK2 inhibitors with enhanced activin-like receptor
kinase selectivity and the potential for reduced off-target effects.
We expect that these encouraging results will contribute to the
pursuit of medicinal chemistry efforts towards the identification
of a future clinical candidate for FOP.
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